KeyCorp Has Lowered Expectations for Progyny (NASDAQ:PGNY) Stock Price

Progyny (NASDAQ:PGNY) had its price objective lowered by equities researchers at KeyCorp from $32.00 to $28.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s target price points to a potential upside of 55.00% from the company’s current price.

Several other equities research analysts have also recently weighed in on PGNY. Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research note on Tuesday, January 20th. Barclays assumed coverage on shares of Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price on the stock. BTIG Research reiterated a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. JPMorgan Chase & Co. set a $35.00 price objective on shares of Progyny in a research note on Wednesday, January 21st. Finally, Truist Financial cut their price objective on shares of Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.80.

Progyny Price Performance

Shares of PGNY opened at $18.07 on Monday. The company has a 50-day simple moving average of $23.90 and a two-hundred day simple moving average of $23.11. The firm has a market capitalization of $1.56 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 1.12 and a beta of 1.01. Progyny has a one year low of $16.75 and a one year high of $28.75.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. During the same quarter in the prior year, the business earned $0.42 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts expect that Progyny will post 0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Progyny

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Progyny by 2.4% during the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after acquiring an additional 235,513 shares in the last quarter. State Street Corp boosted its stake in Progyny by 1.5% during the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Progyny by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after purchasing an additional 20,533 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.